ReviewThe Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2019
Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis.
Review in The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study.Paediatric drugs · 2025Trial
- Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2024Trial
- Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.American journal of clinical dermatology · 2023Trial
- Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis.Genes to cells : devoted to molecular & cellular mechanisms · 2026Article
- Soft drugs: design principles and topical applications.Nature reviews. Drug discovery · 2026Review
- Tapinarof Versus Crisaborole for Pediatric Atopic Dermatitis: A Systematic Review and Meta-Analysis.Dermatology practical & conceptual · 2026Review
- Phosphodiesterase 4 (PDE4) Inhibitor in Atopic Dermatitis: Impact of Nanocrisaborole on Biopharmaceutical Performance and Treatment Outcomes.Mini reviews in medicinal chemistry · 2026Review
- Exploring the Therapeutic Potential of Crisaborole Gel in Atopic Dermatitis: A Review.Recent advances in drug delivery and formulation · 2026Review
- Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs.Biomedicines · 2025Article
- Allergy and dermatology US treatment guidelines review for adults with atopic dermatitis.The journal of allergy and clinical immunology. Global · 2025Article
- Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.Biomolecules & therapeutics · 2025Review
- Comparison of the Effectiveness Differences between Western and Chinese Medicinal Ointments against Eczema.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis.Dermatology and therapy · 2025Article
- Review
- Synthesis and Evaluation of Boron-Containing Heterocyclic Compounds with Antimicrobial and Anticancer Activities.Molecules (Basel, Switzerland) · 2025Article
- Atopic Dermatitis: A Review of Diagnosis and Treatment.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Crisaborole combined with vitamin D demonstrates superior therapeutic efficacy over either monotherapy in mice with allergic contact dermatitis.Scientific reports · 2024Article
- Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectivesMultidisciplinary respiratory medicine · 2024Article
- PJ‑001, a small‑molecule proteolysis‑targeting chimera, ameliorates atopic dermatitis‑like inflammation in mice by inhibiting the JAK2/STAT3 pathway and repairing the skin barrier.Experimental and therapeutic medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.